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Introduction: Llama single domain antibody fragments (VHH), which can pass endothelial barriers, are being
investigated for targeting amyloid plaque load in Alzheimer's disease (AD). Contrary to conventional human or
murine antibodies consisting of IgG or F(ab′)2 antibody fragments, VHH are able to effectively pass the blood
brain barrier (BBB) in vitro. However, in earlier in vivo studies, anti-amyloid VHH showed poor BBB passage
due to their short serum half-lives. It would be of interest to develop a VHH based protein with elongated
serum half-life to enhance BBB passage, allowing the VHH to more easily reach the cerebral amyloid deposits.
Methods: To increase serum persistence, the Fc portion of the human IgG1 antibody (hinge plus CH2 and CH3
domains) was fused to the C-terminus of the VHH (VHH-pa2H-Fc). To determine the pharmacokinetics and
biodistribution proﬁle of the fusion protein, the chelator p-SCN-Bz-DTPAwas linked to the protein and thereafter
labeled with radioactive indium-111 (111In). Double transgenic APPswe/PS1dE9 and wild type littermates were
injected with 20 μg VHH-pa2H-Fc-DTPA-111In (10-20 MBq). Pharmacokinetics of the tracer was determined in
blood samples at 10 intervals after injection and imaging using microSPECT was performed. The biodistribution
of the radioactivity in various excised tissues was measured at 48 h after injection.
Results: We succeeded in the expression of the fusion protein VHH-pa2H-Fc in HEK293T cells with a yield of
50 mg/L growth medium. The fusion protein showed homodimerization – necessary for successful Fc neonatal
receptor recycling. Compared to VHH-pa2H, the Fc tailed protein retained high afﬁnity for amyloid beta on
human AD patient brain tissue sections, and signiﬁcantly improved serum retention of the VHH. However, at
48 h after systemic injection of the non-fused VHH-DTPA-111In and the VHH-Fc-DTPA-111In fusion protein in
transgenic mice, the speciﬁc brain uptake of VHH-Fc-DTPA-111In was not improved compared to non-fused
VHH-DTPA-111In.
Conclusion: Using VHH-Fc conjugates increases the blood half-life of the protein. However, purely extending
the time window for brain uptake does not increase BBB passage. Nevertheless, VHH-Fc holds promise for
therapeutic applications where a sustained systemic circulation of VHH is advantageous.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Due to their long, protruding andhighly variable CDR3 section, llama
derived single domain antibody fragments (VHH) have the ability to
access epitopes normally hidden for conventional antibodies. As such
they are a very successful class of therapeutics, with applications
ranging from interference with enzymatic active sites leading toperformed within the frame-
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Weerd).neutralization of toxins [1–3] and viruses [4], blocking of apoptotic path-
ways in autoimmune diseases [5] and preventing aberrant protein aggre-
gation [6], to binding spatially different amyloid beta (Aβ) depositions [7].
On the other hand, their small size (12–15 kDa) and inherent short
blood half-life can be a hindrance to target their epitopes. Monovalent
VHHmay not have enough time to interact with hard-to-reach epitopes
or to cross regulate endothelial barriers – such as the blood brain barrier
(BBB) – in sufﬁcient amounts [8]. They may be rapidly ﬁltered out of
the system, unless they are injected at very high doses, continuously
via infusion or the BBB is locally impaired [9,10]. Even though for imag-
ing applications short half-lives are interesting [11], for systemic immu-
notherapeutic applications, elongated serum half-lives of VHH are
preferred. For our application of VHH as amyloid targeting therapeutics,
both increased BBB passage and extension of serum half-life would be
desired and the second may prove to be a means to achieve the ﬁrst.
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Fig. 1. Schematic representation of ss-VHH-pa2H-Fc. (A) The llama antibody fragment pa2H is fused to the hinge (H) region and the CH2 and CH3 domains of the crystallizable fragment
(Fc) of the human IgG1. The N-terminal lysozyme secretion signal (ss; amino acid sequence MRSLLILVLCFLPLAALGAQPA) forces the protein to be secreted into the extracellular space.
(B) Due to the fusion of the Fc domain, the VHH-pa2H,which is normally 12 kDa in size,will form two disulﬁde bridges in the attached hinge region and reach a total size of approximately
80 kDa as a homodimeric protein complex.
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achieved by repeated injections or slow infusion administration
[12,13], but a less invasive, and thus preferable way to increase serum
retention is by fusing the antibody fragment to an IgG fragment crystal-
lizable region (Fc, i.e. CH2 and CH3) and the hinge region. Due to the
inherent dimeric nature of the Fc fragment, Fc-VHH fusions are
produced as homodimeric proteins with interchain disulﬁde bridges
between the cysteine amino acids in the hinge region [14]. The total
protein complex size of the dimeric VHH-Fc increases to 80 kDa,
i.e. above the globular ﬁltration molecular weight cut-off limit of the
renal ﬁltration system of the body of approximately 60 kDa. Additional-
ly, the CH2 and CH3 domainswill interact with the neonatal Fc receptor
(FcRn) in early endosomes, favoring recycling and transcytosis over
catabolism, which in turn increases the retention of the protein in
the body [15–17].
The Fc-fusion approach has been performed earlier with single
chain antibody fragments (scFv) [12,13], which are also recombi-
nant antibody fragments. These scFv-Fc fusion proteins have been
produced and applied both in vitro and in vivo[18–20], and studies
indeed show increased blood residential times of the constructs
[21]. VHH-Fc fusion constructs have been developed and produced
in plant cells [22–24] as well as in cultured murine [2] and human
cell lines [5,25]. However, until very recently the in vivo
biodistribution proﬁles of VHH-Fc fusion proteins have not been
extensively reported, with a single reference reporting a generally
increased blood half-life in BALB/c mice [26] and onemore extensive
report showing improved pharmacokinetic potency and increased
BBB passage in Wistar rats [27].
This study reports on the production and validation of an Fc-
fusion VHH directed against human Aβ and the pharmacokinetics
and biodistribution proﬁles of this Fc-fusion VHH in transgenic
APPswe/PS1dE9 mice compared to the unmodiﬁed VHH antibody
fragment. Here we describe the production in human embryonic kidney
cells (HEK293T) and puriﬁcation of anti-Aβ VHH-pa2H fused to the Fc
domain and hinge region of a human IgG1. Furthermore, we determined
whether speciﬁc afﬁnity for Aβ in pathological brain material was
retained for the secreted fusion protein. Finally, we measured and
describe the biodistribution proﬁle and performed SPECT imaging in
mice using the radiolabeled VHH-Fc to show the effect of increased
retention in the blood on BBB passage.2. Material and methods
2.1. Construction of VHH-pa2H-Fc in pINFUSE-hIgG1-Fc1 vector
VHH-pa2Hwas cloned from thepUR5071 vector [7] into an interme-
diate subcloning vector to introduce the chicken lysozyme secretion sig-
nal (ss) [5′-ATGAGGTCTTTGCTAATCTTGGTGCTTTGCTTCCTGCCCCTGGCTG
CTCTGGGG-3′] [28] directly upstream of the VHH (ss-VHH-pa2H). A
BglII and an EcoRI restriction enzyme consensus sequence were intro-
duced respectively upstream and downstream of the ss-VHH sequence
via PCR [fwd. primer BglII: 5′-AGAAGATCTCGCAGCAGCTGAGGAT-3′;
rev. primer EcoRI: 5′-GCAGAATTCATGAGGTCTTTGCTAATCTT-3′]. The
construct was then cloned into a pINFUSE-hIgG1-Fc1 vector (InvivoGEN,
CA, USA) using the introduced restriction sites, to create the ss-VHH-
pa2H-hIgG1-Fc fusion protein construct under the control of a hEF1-
HTLV composite promoter (Fig. 1).
2.2. Production of VHH-pa2H-Fc in HEK293T cells and quality control
The ss-VHH-pa2H-hIgG1-Fc fusion protein was produced in a
HEK293T cell-line under serum-free conditions as described before
[29]. The fusion protein (VHH-pa2H-Fc) contained in the cell-freemedi-
um fraction was afﬁnity puriﬁed using Protein A resin (nProteinA se-
pharose 4 fast ﬂow, GE Healthcare, Leiderdorp, The Netherlands).
After washing with PBS, the VHH-Fc was eluted from the Protein A
resin with 0.1 M sodium citrate at pH 2. Fractions containing the puri-
ﬁed VHH-pa2H-Fc proteins were pooled and neutralized to pH 7.5
with a 1 M NaOH buffer solution and dialyzed against PBS in triplicate
including one step overnight. The amount of puriﬁed peptide was
assessed using the Bradford assay and Nanodrop® spectral absorption
at 280 nm. The purity of VHH-pa2H-Fc was determined with size
exclusion chromatography on an ÄKTA FPLC system (GE Healthcare)
using a size exclusion column (SuperdexTM 75 10/300 GL). To conﬁrm
the formation of the homodimeric VHH-Fc products, puriﬁed samples
of VHH-pa2H-Fc were run on SDS-PAGE under reducing and non-
reducing conditions. Reduced VHH-pa2H-Fc samples were prepared
with dithiothreitol (DTT, Sigma, Zwijndrecht, The Netherlands), whereas
in the non-reducing conditions DTT was omitted. Puriﬁed VHH-pa2H-Fc
was stored at 4 °C until use. For comparison studies non-fused VHH-pa2H
was produced as described before [8].
Fig. 2. HEK293T production of VHH-pa2H-Fc. (A) Transfection of HEK293T cells with the
pINFUSE-ss-pa2H-Fc vector and PEI transfection reagent consistently yields high transfection
efﬁciencies. Blue channel shows DAPI stained nuclei, green channel VHH-pa2H-Fc stained
with mouse anti hIgG1 and AlexaFluor-488-goat anti mouse. White bar indicates 75 μm.
(B) Western blot analysis of the effect of Fetal Calf Serum (FCS) in the medium indicates
the need for FCS during the ﬁrst 24 h after transfection. Lanes 1 and 2 = 0% FCS, lanes
3 and 4 = 10% FCS during the ﬁrst 24 h, 0% FCS during the second 24 h, lanes 5 and 6 =
10% FCS. Samples were taken 48 h after transfection. L = cell lysate sample, M = cell-free
medium sample. Bands run at approximately 42 kDa. Primary antibody: mouse anti hIgG1.
Secondaryantibody: IRD-CW800-goat antimouse. (C)VHH-pa2H-Fc secreted into the cellme-
dium at 0 h, 24 h, 48 h and 72 h after switching to FCS freemedium at 24 h after transfection
(lanes 1–4 respectively) indicate immediate and effective secretion of the produced VHH-Fc
fusionprotein. Bands run at approximately 42 kDa. Primary antibody:mouse anti hIgG1. Sec-
ondary antibody: IRD-CW800-goat anti mouse.×200).
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To conﬁrm the retained afﬁnity of VHH-pa2H-Fc and VHH-pa2H-Fc-
DTPA for Aβ depositions, immunoﬂuorescence staining was performed
on human post-mortem AD brain and aged matched healthy control
cryosections. All human tissues were obtained from anonymous
patients or healthy aged donors as conﬁrmed by neuropathological
examination in agreement with the guidelines of the Medical Ethics
Committee of the Leiden University Medical Center (Leiden, The
Netherlands). All tissues were processed in a coded fashion, according
to Dutch national ethical guidelines (Code for Proper Secondary Use of
Human Tissue, Dutch Federation of Medical Scientiﬁc Societies). Brieﬂy,
acetone ﬁxed serial cryosections (5 μm)were blocked for 1–2 hwith 4%
milk powder (Marvel dried skimmed milk powder, Premier Foods, UK)
in PBS (mPBS). Blocked sectionswere incubated overnightwith 20ng/μl
puriﬁed VHH-pa2H-Fc. After 3× 5min washing steps with PBS, the sec-
tions were exposed to mouse anti human IgG1 (1:500, m1325 Sanquin
Peliclass, Leiden, The Netherlands) for 1–2 h, washed and then incubat-
ed with Alexa Fluor 488 – goat anti mouse (1:500, A-11001, Life Tech-
nologies, CA, USA) for 1 h. To conﬁrm Aβ presence, adjacent mPBS
blocked sections were incubated with mouse anti Aβ (4G8, Covance,
Rotterdam, The Netherlands) for 1 h, washed and then incubated with
Alexa Fluor 594 – goat anti mouse (1:500, A-11032, Life Technologies)
for 1 h. All antibody dilutions were performed in mPBS. Fluorescencesignal was detected on a Leica DM5500B microscope with a Leica
DFC360FX camera and analyzed with Leica LAS-AF v 2.3.6 software
(Leica Microsystems, Rijswijk, The Netherlands). Whole slide overview
images were acquired with a BZ-9000 BIOREVO HS All-in-One Fluores-
cence microscope (Keyence, Mechelen, Belgium).
2.4. DTPA conjugation to VHH-pa2H-Fc and radiolabeling with 111Indium
To enable the radiolabeling of the VHH with 111Indium (111In), the
chelator p-SCN-Bz-DTPA (C22H28N4O10S•3HCl, MW 649.92 g/mol,
Macrocyclics Inc. Dallas TX, USA) was conjugated to primary amine
groups on the VHH-pa2H-Fc fusion protein as described previously
[8]. In short, a 5× molar excess of the chelator was incubated with
VHH-pa2H-Fc at 37 °C for 3 h in PBS (pH 8.2) and dialyzed against the
labeling buffer 250 mM ammonium acetate at pH 5.5 for at least three
times at 4 °C including one overnight step. Conjugated and dialyzed
preparations were stored in the dark at 4 °C.
Before in vivo use, the VHH-pa2H-Fc-DTPA constructwas radiolabeled
with 111In through incorporation of the isotope into the DTPA chelator as
described before [8]. In short, 111InCl3 (Covidien, The Netherlands) was
added to theDTPA conjugatedVHH-Fc, incubated at 37 °C in 250mMam-
monium acetate buffer at pH 5.5 for 3 h under gentle shaking, and then
puriﬁed with a PD-10 desalting column (GE Healthcare) in 20 elution
fractions of 0.5 ml PBS. Fractions containing radioactive 111In-labeled
VHH-pa2H-Fc-DTPA (VHH-pa2H-Fc-DTPA-111In) were pooled and used
for animal studies. The amount of 111InCl3 added to the labeling solution
was adjusted depending on radiation strength upon delivery to yield
20 μg of VHH-pa2H-Fc-DTPA-111In at 10–20 MBq per injection.
2.5. Pharmacokinetics
All in vivo studies were performed using 12–16 month old double
transgenic mice (n = 4–8) from a colony set up using the APPswe/PS1dE9
strain (APP/PS1; JAX® Mice and Services, The Jackson Laboratory, Bar
Harbor ME, USA) on a C57BL/6 background and their wild type litter-
mates (WT). The strain is known to rapidly develop a vascular (CAA)
and parenchymal Aβ associated phenotype [30–32]. Animals were kept
on a strict 12 hour day/night light cycle with unlimited access to normal
chow and water. All animal studies have been approved by the Leiden
University Medical Center institutional Animal Ethics Committee (DEC
permits 10097 and 12065). Besides standard genotyping, Aβ pathology
was conﬁrmed on brain sections by standard Thioﬂavin T staining [10].
Animals were injected intravenously with 20 μg VHH-pa2H-Fc-
DTPA-111In (10-20 MBq). At 0.5, 2, 3, 4, 6, 22, 24, 26, 28, and approxi-
mately 48 h after injection 5 μl blood samples were taken from the tail
vein and counted for radioactivity. After radioactive decay correction,
the total injected dose (ID), blood clearance rates, area under the
curve values (AUC) and standard uptake values (SUV, i.e. the percentage
of the ID per gram blood – or gram tissue – per gram mouse) in blood
were calculated as described before [8].
2.6. MicroSPECT imaging
To visually analyze the biodistribution proﬁles, transgenic and WT
animals, injected with the radiolabeled VHH-pa2H-Fc-DTPA-111In,
were imaged for 40 minutes under continuous 1–2% isoﬂurane
inhalation anesthesia on a three-headed U-SPECT-II microSPECT
(MILabs, Utrecht, The Netherlands) at 48 h after administration of the
radiolabeled VHHusing a 0.6mmmouse pinhole collimator, and energy
setting at 171 keVwith awindowof 20% [8]. Total body imageswere re-
constructed using six POSEM iterations with 16 subsets, a 0.2 mmvoxel
size and with decay and scatter corrections integrated into the recon-
struction using dedicated MILabs reconstructions software. Volume-
rendered images were generated and analyzed using a freeware tool
from Amide.exe 1.0.2 Medical Image Data Examiner (http://amide.
sourceforge.net) [8,33].
AD
AD
HC
VHH-pa2H-Fc-DTPAmouse anti Aß (4G8)VHH-pa2H-Fc
Fig. 3. IHC on serial sections of postmortempatient brainmaterial (AD) and agedmatched control (HC) stained for amyloid deposits with either VHH-pa2H-Fc (left: green) or VHH-pa2H-
Fc-DTPA (right: green) or 4G8 (middle: red) show outstanding and highly speciﬁc recognition of VHH-pa2H-Fc for both vascular and parenchymal Aβ, regardless of DTPA conjugation.
Secondary antibody: mouse anti human IgG for the VHH; AlexaFluor 594 goat anti mouse for the 4G8 staining. Tertiary antibody for VHH-pa2H-Fc and VHH-pa2H-Fc-DTPA only:
AlexaFluor 488 goat anti mouse. Nuclei stained in blue with DAPI. Top row images represent vascular and parenchymal amyloid deposits, middle row shows the remainder of the section
and bottom row images show representative of parenchymal and vascular areas in aged matched healthy controls devoid of Aβ deposits. White bars indicate 75 μm.
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Directly after imaging and collecting the last blood sample, the mice
were euthanized and perfused with 15 ml PBS [8]. Thereafter, the
bladder including urine, heart, lungs, spleen, liver, both kidneys, part
of the left femoral muscle, cerebrum and cerebellum were removed.
All tissues and organs were weighed and counted for radioactivity
using a Wizard2 2470 automatic gamma scintillation counter (Perkin
Elmer, MA, USA) and obtained measurements of radioactivity uptake
in tissues and organs were calculated and reported as SUV.
2.8. Statistical analysis
All data are presented as mean value (±SEM) of 4–8 independent
measurements. Statistical analysis for differences between groups in
the animal studies were performed by Student's paired t-test with
one-tailed distribution. Signiﬁcance was assigned for p-values of
b0.05. All analyses and calculations were performed using Microsoft®
Ofﬁce Excel 2010 and GraphPad Prism version 5.01 for Windows
(GraphPad Software, San Diego, CA, USA).
3. Results
3.1. VHH-pa2H-Fc production and quality control
Transfection of pINFUSE-ss-pa2H-Fc into HEK293T cells yielded high
transfection efﬁciencies (Fig. 2A) and nearly immediate production
and secretion of the fusion protein (Fig. 2B and C). The best productionand puriﬁcation of VHH-pa2H-Fc were obtained with transfection in
medium supplemented with fetal calf serum (FCS) and maintained in
FCS-free conditions from 24 h after transfection. This set-up yielded
50 mg secreted VHH-pa2H-Fc per liter growth medium, at an average
ﬁnal concentration after puriﬁcation and dialysis of 1.0 mg/ml
VHH-pa2H-Fc in PBS.
The produced and secreted VHH-pa2H-Fc and the VHH-pa2H-Fc-
DTPA both retained functional speciﬁcity for Aβ depositions in plaques
and around vessel walls in brain tissue sections from human patient ma-
terial and does not show a speciﬁc binding in control tissue (Fig. 3). The
immunoreactivity is highly similar to conventional monoclonal anti-Aβ
antibodies (e.g. clone 4G8) and to the speciﬁcity previously shown by un-
modiﬁed VHH-pa2H [7,8,10,30]. Addition of the chelator DTPA to VHH-
pa2H-Fc did not impair the ability to recognize and bind Aβ.
3.2. VHH-pa2H-Fc dimerization
For interaction of the VHH-Fc with FcRn, which is necessary to pro-
long the blood half-life, the fusion protein must form disulﬁde bridge
based dimers as shown in Fig. 1. The formation of the homodimers
was conﬁrmed on SDS-PAGE under reducing and non-reducing condi-
tions. Under reducing conditions the VHH-Fc fusion protein ran at the
expected monomer height of approximately 40 kDa (Fig. 4A). The sam-
ples under non-reducing conditions showed a higher band on gel, indi-
cating the presence of a homodimeric protein complex. The exact size of
the higher bands cannot be determined in this experiment, as bands
resulting from non-reduced proteins cannot be compared with the
used marker. However, with size exclusion chromatography (SEC) a
Fig. 4. Quality control of 2H-Fc, 2H-Fc-DTPA and 2H-Fc-DTPA-111In. (A) SDS-PAGE analysis of VHH-pa2H-Fc under denaturing (+DTT) and non-denaturing (−DTT) conditions shows a
denatured protein at approximately 42 kDa andmuch higher bands under non-denaturing conditions, indicating the formation of a complex protein. (B and C) Size exclusion chromatog-
raphy conﬁrms the addition of at least one DTPA molecule to VHH-pa2H-Fc as indicated by the near-complete shift of the peak from 11.44 to 18.69 ml. (D) PD-10 column puriﬁcation
indicated highly successful radiolabeling of 111In to the DTPA labeled VHH-pa2H-Fc, as no signiﬁcant peaks were detected in fractions 12–18, in which free radiotracer elutes from
the column.
699M. Rotman et al. / Nuclear Medicine and Biology 42 (2015) 695–702mass of approximately 83,900 Da was determined, which is in concor-
dance with the theoretical size of a VHH-pa2H-Fc homodimer (Fig. 4B).
3.3. DTPA conjugation to VHH-pa2H-Fc and radiolabeling with 111Indium
Successful DTPA conjugation to the fusion protein was conﬁrmed
with size-exclusion chromatography, in which the retention time of
the peak for the non-radiolabeled VHH-pa2H-Fc almost completely
shifted from 11.44 to 18.69 ml (Fig. 4B and C). After radiolabeling,
VHH-pa2H-Fc-DTPA-111In was puriﬁed on a PD-10 column to remove
labeling reactants. The highest radioactivity was found in fractions 6–9
(Fig. 4D), which were pooled for in vivo administration. No signiﬁcant
peaks were detected in the shoulder in fractions 12–18, indicating the
absence of free 111In. The amount of radioactivity in the pooled fractions
amounted to 89% of the total radioactivity.
3.4. Pharmacokinetics
The blood clearance of the VHH fusion protein VHH-pa2H-Fc-DTPA-
111In and control tracer VHH-pa2H-DTPA-111In were calculated and
expressed as SUV, from which the AUC was calculated (Fig. 5). Based
on the AUC values and clearance graphs it is clear that the fusion of
the human IgG Fc domain leads to a signiﬁcant increase in retention in
the blood of the fused VHH compared to the unmodiﬁed VHH-pa2H(Fig. 5). Even though slightly higher in the transgenic group, between
the APP/PS1 group and theWT littermates the AUC of the blood clearance
of VHH-pa2H-Fc-DTPA-111In was not signiﬁcantly different.
3.5. MicroSPECT imaging
MicroSPECT imaging of themice injectedwith VHH-pa2H-Fc-DTPA-
111In conﬁrmed that the Fc-fused VHH was still present in the mice at
48 h, mainly in the renal cortex and in the liver (Fig. 6). However, the
images depicted clearly that the proteinwas not found to be accumulat-
ing in the transgenic brains, i.e. at the amyloid deposits, as there was
no signiﬁcant difference in signal in that area between APP/PS1 and
WT animals.
3.6. Biodistribution
Radioactivity counts of excised organs and tissues at 48 h after injec-
tion showed that the proﬁles of the Fc tagged VHH generally follow the
plasma pharmacokinetics, i.e. higher counts are found in the organs for
the VHH-pa2H-Fc-DTPA-111In group compared to the non-Fc group
(Table 1). The kidneys are themain organ of clearance of the radioactiv-
ity of VHH-pa2H-Fc-DTPA-111In, corroborating the SPECT data. For the
non-fused VHH, 98.10 %ID ± 0.04 is secreted after 48 h, with the re-
mainder residing mainly in the spleen. This secretion is signiﬁcantly
Fig. 6. Anterior and lateral microSPECT scintigraphs show the difference in bio-distribu-
tion and pharmacokinetic proﬁle of VHH-pa2H-Fc-DTPA-111In between APPswe/PS1dE9
transgenic (APP/PS1) mice and wild type littermates (WT) at 48 h after injection. In
both strains, the majority of the signal originates from the kidneys (3) and the liver (2),
while the brain (1) does not containmore signal compared to the rest of the body. Overall,
there seems to be less signal originating from the WT animal compared to the APP/PS1,
which is in concordance with the data obtained from the pharmacokinetics. All mice
were injected with 20 μg VHH labeled with 111In at 10–20 MBq at the time of injection
and imaged at 48 h for 30 minutes.
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Fig. 5. Pharmacokinetics. (A) Blood clearance of VHH-pa2H-Fc and VHH-pa2H labeled
with 111In in double transgenic APPswe/PS1dE9 mice (APP/PS1) and wild type littermates
(WT). Data are mean ± SEM of 4–8 observations at time points up to 48 h after injection
and are shown as standard uptake value (SUV). (B) Area under the curve (AUC) values
show signiﬁcant increases for the Fc fused VHH compared to the non-fused pa2H.
⁎P b 0.05 compared to VHH-pa2H-DTPA-111In. N/A = not applicable, nd = not deter-
mined. All mice were injected with 20 μg VHH labeled with 111In at 10–20 MBq at the
time of injection.
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111In in both transgenic (92.47 %ID ± 0.59) and WT littermates (94.77
%ID ± 0.19) at 48 h after injection. For VHH-pa2H-Fc-DTPA-111In the
excretion was signiﬁcantly lower (P b 0.01) in APP/PS1 mice compared
to WT.
When analyzing the amount of radioactivity found in the brain, it is
interesting to note that the brain to blood ratio seems to be signiﬁcantly
higher for the non-fused VHH than for the Fc fused moieties. However,
by comparing this ratio to themuscle to blood ratio, a calculationwhich
indicates the speciﬁcity of the brain to blood ratio, it is clear that the ex-
ceedingly low blood values in the non Fc fused VHH group are con-
founding the obtained ratios. The ratio “brain/blood to muscle/blood”
is not signiﬁcantly different between any of the analyzed groups.
4. Discussion
In this study we provide evidence that the blood clearance of VHH-
pa2H-DTPA-111In in WT and APP/PS1 transgenic mice can be signiﬁ-
cantly slowed down by fusion to the Fc region of the human IgG protein.
Earlier we have shown that free, unmodiﬁed VHH have a fast blood
clearance proﬁle and may not efﬁciently cross the in vivo BBB; a limita-
tion which must be overcome for the development of brain amyloid
targeted diagnostics or therapeutics in AD [8,10]. The rapid renal clear-
ance of non-Fc tagged VHH-pa2H-DTPA-111In is oncemore conﬁrmed in
this study (Fig. 5 and Table 1).
As the transport of these Aβ-targeting VHH over the BBB is an active
process [30,34,35], we hypothesized that prolonging the blood residen-
tial time of the VHH could increase its delivery into the brain. To achieve
this, a human IgG1 Fc domain (hinge, CH2 and CH3 region)was fused to
the C-terminus of VHH-pa2H (Fig. 1). As a result the homodimer
forming fusion protein reaches a total molecular weight of 80 kDa,
above the renal ﬁltration cut-off of approximately 60 kDa. Furthermore,
interaction of the fusion protein with the FcRn provides additional
systemic retention of the construct. As the increased AUC values show,
the fusion of the Fc domain did indeed signiﬁcantly prolong the blood
residential time of VHH-pa2H-DTPA-111In (Fig. 5).
Between the two groups of mice – the APP/PS1 double transgenic
and the WT littermates – there is no signiﬁcant difference in retention
of VHH-pa2H-Fc-DTPA-111In. This indicates that indeed the presence
of the Fc tail, rather than the presence of an Aβ phenotype, is the
cause of the increased retention in the circulation, even if the trend in
the AUC graph and values indicates a slightly higher retention in the
APP/PS1 animals (Fig. 5). This trend is also observed in the microSPECT
images obtained at 48 hours after injection, in which certain organs,
most notably the kidneys and the liver, seem to have a slightly stronger
signal (Fig. 6). In accordance, less radioactivitywas excreted from trans-
genic mice compared to WT at 48 h.
The pharmacokinetics data (Fig. 5) furthermore suggest a dramatic
reduction in volume of distribution (VD) as a result of the fusion of the
Fc tail. This is especially pronounced in the WT group injected with
VHH-pa2H-Fc-DTPA-111In. This would indicate that the unmodiﬁed
VHH-pa2H-DTPA-111In is more rapidly distributed over the organs
and tissues in the animal body, while the Fc-fused protein remains in
the bloodstream. However, keeping in mind that unmodiﬁed VHH
have signiﬁcantly shorter blood half-lives and are quickly cleared by
the renal system, it must be noted that the organ biodistribution proﬁle
should be analyzed shortly after injection to conﬁdently calculate actual
VD values.
The biodistribution data (Table 1) show that most organs in the
groups injected with the VHH-pa2H-Fc-DTPA-111In have signiﬁcantly
higher SUVs compared to the non-fused VHH.However, when the ratios
between the brain-to-blood and muscle-to-blood are compared, it is
clear that there is no relative increase in uptake in the brain compared
to uptake in the muscle. Interestingly, there is no speciﬁc increase in
the brains of the transgenic animals compared to the WT littermates
either. In previous studies, it has been shown that once the VHH reaches
Table 1
Biodistribution of VHH-pa2H-DTPA-111In and VHH-pa2H-Fc-DTPA-111In in 12–14 month old APPswe/PS1dE9 mice (APP/PS1) and wild type littermates (WT) at 48 h post injection.
Tissue VHH-pa2H-DTPA-111In VHH-pa2H-DTPA-111In
WT APP/PS1 WT APP/PS1
n - 4 8 8
SUV ± SEM nSUV = %ID/g tissue per g mouse
Blood nd 0.0007 ± 0.0001 0.0194 ± 0.0034⁎ 0.0242 ± 0.0149⁎,¶
Urine and bladder nd 0.0291 ± 0.0079 0.0237 ± 0.0036 0.0140 ± 0.0025
Heart nd 0.0015 ± 0.0003 0.0099 ± 0.0011⁎ 0.0121 ± 0.0022⁎,¶
Lungs nd 0.0016 ± 0.0002 0.0188 ± 0.0018⁎ 0.0188 ± 0.0035⁎,¶
Spleen nd 0.2939 ± 0.1362 0.0412 ± 0.0072⁎ 0.0207 ± 0.0037⁎,¶
Liver nd 0.0007 ± 0.0001 0.0658 ± 0.0108⁎ 0.0135 ± 0.0091
Kidneys nd 0.1493 ± 0.0095 0.2194 ± 0.0119⁎ 0.0874 ± 0.0455
Muscle nd 0.0008 ± 0.0001 0.0054 ± 0.0012 0.0048 ± 0.0009⁎,¶
Cerebrum nd 0.0001 ± 0.0000 0.0011 ± 0.0004 0.0008 ± 0.0003
Cerebellum nd 0.0003 ± 0.0003 0.0007 ± 0.0001⁎ 0.0008 ± 0.0002⁎
Brain nd 0.0004 ± 0.0002 0.0017 ± 0.0005 0.0016 ± 0.0005
Brain/blood ratio nd 0.5796 ± 0.1546 0.0829 ± 0.0059⁎ 0.0640 ± 0.0066⁎,¶
Muscle/blood ratio nd 1.3040 ± 0.4035 0.3192 ± 0.0761⁎ 0.2225 ± 0.0219⁎,¶
Ratio brain/blood to muscle/blood nd 0.4376 ± 0.1083 0.3719 ± 0.1041 0.3157 ± 0.0629
Values are presented as the mean ± SEM values of the radioactivity counted per weighed tissue after sacriﬁcing and corrected for total body weight expressed as the standard uptake
value (SUV) of 4–8 observations. All values are corrected for radioactive decay over time, nd = not determined. All mice were injected with 20 μg VHH labeled with 111In at
10–20 MBq at the time of injection and blood and all tissues were obtained at 48 h after injection.
⁎ P b 0.05 compared to VHH-pa2H.
¶ P b 0.05 compared to WT mice.
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ciated with the amyloid and will thus be retained in the brain [8,10]. It
can therefore be assumed that VHH-pa2H-Fc-DTPA-111In does not
reach the BBB protected brain more efﬁciently than the non-fused
VHH-DTPA-111In, despite the increased blood circulation time.
The 80 kDa size of the VHH-Fc, a signiﬁcant increase over the 12 kDa
of the unmodiﬁed VHH, may hypothetically obstruct the blood brain
barrier passage. However, an increase in size of the VHHdoes not neces-
sarily exclude brain barrier passage [9]. Even full length IgGs can be
transported over the BBB when an active transport is involved [36,37],
as is the casewith the VHHs. Indeed, Farrington et al. recently described
the enhanced in vivo passage of an Fc tagged VHH compared to the free
VHH over the rat BBB [27]. It must be noted however, that in the latter
example a 5–15 times higher concentration of VHH-Fc derivative had
been injected compared to the current study and species differences
might play a role in the amount of BBB penetration [38].
The VHH-pa2H-Fc construct does, however, recognize Aβ (Fig. 3).
Fusion of the Fc region to the antibody fragment is therefore not detri-
mental to its function, and may in fact improve the binding capacity
[27]. As a result, VHH-pa2H-Fc could still be used for peripheral applica-
tions in general andmore speciﬁcally investigated for use in the periph-
eral sink theory [39–41]. Furthermore, it also means that the concept of
VHH-Fc fusion proteins can be extrapolated to other VHHs. In this study
we did not examinewhether theVHH-pa2H-Fc-DTPA-111In in the blood
is free in the plasma or bound to circulating host cells. It may be plausi-
ble that the interaction of the fusion protein with Fc receptors or other
compounds increases the blood residential time, but also actively pre-
vents the fusion protein to reach and cross the BBB [42].
The use of the chelator p-SCN-Bz-DTPA to label VHH-pa2H and VHH-
pa2H-Fcwith 111In could cause theVHHto act differently in an in vivo setting.
However, based on the experiments in this study (Fig. 3) and on previous
experience, we know that the DTPA labeling has no effect on the amyloid
beta binding characteristics of the VHH [8,10], and that the labeling itself is
very stable over time [8]. Also, it has been shown that conjugation with
Alexa dyes, which occurs via a similar NHS-ester conjugation, shows no
difference in characteristic binding or biodistribution proﬁles for single
VHHs [10], or for Fc conjugated VHHs [27] and that the similar binding of a
NOTA chelator can be used to follow the biodistribution of VHHs in vivo [43].
5. Conclusion
VHH-pa2H-Fc can be effectively produced in HEK293T cells and
retains its biological activity. It shows signiﬁcantly increased systemicretention due to the fusion of the llama antibody fragment to
the hinge, CH2 and CH3 domains of a human IgG1. However, increasing
the blood circulation time alone does not result in increased
BBB penetration.
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